Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
- PMID: 31196984
- PMCID: PMC7745125
- DOI: 10.1126/science.aau6323
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Abstract
The human gut microbiota metabolizes the Parkinson's disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are unknown. Here, we describe an interspecies pathway for gut bacterial l-dopa metabolism. Conversion of l-dopa to dopamine by a pyridoxal phosphate-dependent tyrosine decarboxylase from Enterococcus faecalis is followed by transformation of dopamine to m-tyramine by a molybdenum-dependent dehydroxylase from Eggerthella lenta These enzymes predict drug metabolism in complex human gut microbiotas. Although a drug that targets host aromatic amino acid decarboxylase does not prevent gut microbial l-dopa decarboxylation, we identified a compound that inhibits this activity in Parkinson's patient microbiotas and increases l-dopa bioavailability in mice.
Copyright © 2019, American Association for the Advancement of Science.
Figures




Comment in
-
Gut microbes metabolize Parkinson's disease drug.Science. 2019 Jun 14;364(6445):1030-1031. doi: 10.1126/science.aax8937. Science. 2019. PMID: 31196998 No abstract available.
-
Drug Metabolism as a Community Effort.Cell Metab. 2019 Aug 6;30(2):235-237. doi: 10.1016/j.cmet.2019.07.005. Cell Metab. 2019. PMID: 31390549
-
The gut microbiota: A novel therapeutic target in Parkinson's disease?Parkinsonism Relat Disord. 2019 Sep;66:265-266. doi: 10.1016/j.parkreldis.2019.08.010. Epub 2019 Aug 12. Parkinsonism Relat Disord. 2019. PMID: 31445904 No abstract available.
Similar articles
-
Targeting bacterial and human levodopa decarboxylases for improved drug treatment of Parkinson's disease: Discovery and characterization of new inhibitors.Eur J Pharm Sci. 2025 Aug 1;211:107133. doi: 10.1016/j.ejps.2025.107133. Epub 2025 May 20. Eur J Pharm Sci. 2025. PMID: 40403986
-
Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.CNS Neurosci Ther. 2024 Feb;30(2):e14383. doi: 10.1111/cns.14383. Epub 2023 Aug 1. CNS Neurosci Ther. 2024. PMID: 37528534 Free PMC article.
-
Time-Resolved Evaluation of L-Dopa Metabolism in Bacteria-Host Symbiotic System and the Effect on Parkinson's Molecular Pathology.Small Methods. 2025 Mar;9(3):e2400469. doi: 10.1002/smtd.202400469. Epub 2024 Jul 26. Small Methods. 2025. PMID: 39058017 Free PMC article.
-
Relationship Between Gut Bacteria and Levodopa Metabolism.Curr Neuropharmacol. 2023;21(7):1536-1547. doi: 10.2174/1570159X21666221019115716. Curr Neuropharmacol. 2023. PMID: 36278467 Free PMC article. Review.
-
Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.Amino Acids. 2002;23(1-3):57-63. doi: 10.1007/s00726-001-0110-x. Amino Acids. 2002. PMID: 12373519 Review.
Cited by
-
Advancing Our Understanding of Pyranopterin-Dithiolene Contributions to Moco Enzyme Catalysis.Molecules. 2023 Nov 7;28(22):7456. doi: 10.3390/molecules28227456. Molecules. 2023. PMID: 38005178 Free PMC article. Review.
-
Probiotics for Parkinson's disease: Current evidence and future directions.JGH Open. 2020 Nov 20;5(4):414-419. doi: 10.1002/jgh3.12450. eCollection 2021 Apr. JGH Open. 2020. PMID: 33860090 Free PMC article.
-
Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism.Front Aging Neurosci. 2022 Nov 2;14:976316. doi: 10.3389/fnagi.2022.976316. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36408101 Free PMC article. Review.
-
A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics-Leveraging Principles of Systems Biology.Pathogens. 2023 Feb 2;12(2):238. doi: 10.3390/pathogens12020238. Pathogens. 2023. PMID: 36839510 Free PMC article. Review.
-
Microbiome-Specific Statistical Modeling Identifies Interplay Between Gastrointestinal Microbiome and Neurobehavioral Outcomes in Patients With Autism: A Case Control Study.Front Psychiatry. 2021 Oct 20;12:682454. doi: 10.3389/fpsyt.2021.682454. eCollection 2021. Front Psychiatry. 2021. PMID: 34744810 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases